BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 33191940)

  • 1. Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.
    Zhang J; Thorikay M; van der Zon G; van Dinther M; Ten Dijke P
    J Vis Exp; 2020 Oct; (164):. PubMed ID: 33191940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.
    Norita R; Suzuki Y; Furutani Y; Takahashi K; Yoshimatsu Y; Podyma-Inoue KA; Watabe T; Sato Y
    Cancer Sci; 2017 Mar; 108(3):419-426. PubMed ID: 28064471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
    Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
    Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation.
    Chen H; Yang T; Wang MC; Chen DQ; Yang Y; Zhao YY
    Phytomedicine; 2018 Mar; 42():207-218. PubMed ID: 29655688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spheroid assay to measure TGF-β-induced invasion.
    Naber HP; Wiercinska E; Ten Dijke P; van Laar T
    J Vis Exp; 2011 Nov; (57):. PubMed ID: 22126971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells.
    Cheng JC; Auersperg N; Leung PC
    PLoS One; 2012; 7(8):e42436. PubMed ID: 22905131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of TGF-β1 Receptor Inhibitor GW788388 on the Epithelial to Mesenchymal Transition of Peritoneal Mesothelial Cells.
    Lho Y; Do JY; Heo JY; Kim AY; Kim SW; Kang SH
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells.
    Kim J; Kong J; Chang H; Kim H; Kim A
    Oncotarget; 2016 Dec; 7(51):85021-85032. PubMed ID: 27829223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smad2/3/4 Pathway Contributes to TGF-β-Induced MiRNA-181b Expression to Promote Gastric Cancer Metastasis by Targeting Timp3.
    Zhou Q; Zheng X; Chen L; Xu B; Yang X; Jiang J; Wu C
    Cell Physiol Biochem; 2016; 39(2):453-66. PubMed ID: 27383203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition.
    Reka AK; Kurapati H; Narala VR; Bommer G; Chen J; Standiford TJ; Keshamouni VG
    Mol Cancer Ther; 2010 Dec; 9(12):3221-32. PubMed ID: 21159608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ski prevents TGF-β-induced EMT and cell invasion by repressing SMAD-dependent signaling in non-small cell lung cancer.
    Yang H; Zhan L; Yang T; Wang L; Li C; Zhao J; Lei Z; Li X; Zhang HT
    Oncol Rep; 2015 Jul; 34(1):87-94. PubMed ID: 25955797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer.
    Dhasarathy A; Phadke D; Mav D; Shah RR; Wade PA
    PLoS One; 2011; 6(10):e26514. PubMed ID: 22028892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mediator of phosphorylated Smad2/3, evodiamine, in the reversion of TAF-induced EMT in normal colonic epithelial cells.
    Yang W; Gong X; Wang X; Huang C
    Invest New Drugs; 2019 Oct; 37(5):865-875. PubMed ID: 30488243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TSC1 activates TGF-β-Smad2/3 signaling in growth arrest and epithelial-to-mesenchymal transition.
    Thien A; Prentzell MT; Holzwarth B; Kläsener K; Kuper I; Boehlke C; Sonntag AG; Ruf S; Maerz L; Nitschke R; Grellscheid SN; Reth M; Walz G; Baumeister R; Neumann-Haefelin E; Thedieck K
    Dev Cell; 2015 Mar; 32(5):617-30. PubMed ID: 25727005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Berberine Suppresses EMT in Liver and Gastric Carcinoma Cells through Combination with TGF
    Du H; Gu J; Peng Q; Wang X; Liu L; Shu X; He Q; Tan Y
    Oxid Med Cell Longev; 2021; 2021():2337818. PubMed ID: 34712379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition.
    Lv ZD; Kong B; Li JG; Qu HL; Wang XG; Cao WH; Liu XY; Wang Y; Yang ZC; Xu HM; Wang HB
    Oncol Rep; 2013 Jan; 29(1):219-25. PubMed ID: 23129177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-β1 induced transdifferentiation of rpe cells is mediated by TAK1.
    Dvashi Z; Goldberg M; Adir O; Shapira M; Pollack A
    PLoS One; 2015; 10(4):e0122229. PubMed ID: 25849436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.
    Peng SB; Yan L; Xia X; Watkins SA; Brooks HB; Beight D; Herron DK; Jones ML; Lampe JW; McMillen WT; Mort N; Sawyer JS; Yingling JM
    Biochemistry; 2005 Feb; 44(7):2293-304. PubMed ID: 15709742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-190 suppresses breast cancer metastasis by regulation of TGF-β-induced epithelial-mesenchymal transition.
    Yu Y; Luo W; Yang ZJ; Chi JR; Li YR; Ding Y; Ge J; Wang X; Cao XC
    Mol Cancer; 2018 Mar; 17(1):70. PubMed ID: 29510731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prohaptoglobin inhibits the transforming growth factor-β-induced epithelial-to-mesenchymal transition in vitro by increasing Smad1/5 activation and suppressing the Smad2/3 signaling pathway in SK-Hep1 liver cancer cells.
    Oh MK; Joo H; Kim IS
    PLoS One; 2022; 17(5):e0266409. PubMed ID: 35580109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.